# Pomegranate Sleep Latency Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/pomegranate-sleep-latency-randomized-trial-evidence-review
Category: evidence-review
Summary: Pomegranate Sleep Latency Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass 
Last reviewed: 2026-07-30
Reviewed by: Migaku Evidence Review
# Pomegranate Sleep Latency Randomized Trial: What the Evidence Says

## Quick Answer

Pomegranate Sleep Latency Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Probiotic Bacteria in Stimulating Human Physiological Responses: Metabolic Function and Overall Health | narrative review | 3 | 2026-06-08 | 10.3390/foods15122079 |
| Impact of Gut–Brain Axis and Probiotics on Alzheimer’s Disease | narrative review | 3 | 2025-09-24 | 10.3390/neurolint17100153 |

## What The Sources Report

- The regulatory classification of probiotics, however, is not uniform and may vary depending on their intended use, formulation, route of administration, and associated health claims. [Chong Shin-Yee (2026); evidence level 3]
- Another goal is to consolidate current evidence on the gut-brain axis and its role in neurodegenerative diseases. [Tabaza Raghad (2025); evidence level 3]
- There is, however, increasing scientific studies and evidence around the role of the gut-brain axis and dietary interventions on AD pathology. [Tabaza Raghad (2025); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For pomegranate sleep latency randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Chong Shin-Yee (2026). Probiotic Bacteria in Stimulating Human Physiological Responses: Metabolic Function and Overall Health. DOI: 10.3390/foods15122079. PMCID: PMC13297772. PMID: 42354045. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13297772/
- Tabaza Raghad (2025). Impact of Gut–Brain Axis and Probiotics on Alzheimer’s Disease. DOI: 10.3390/neurolint17100153. PMCID: PMC12566682. PMID: 41149774. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12566682/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.